Skip to Main Content

Author Details

Stuart Weston
University of Maryland School of Medicine
2014
34
21
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36285523Exhaled Breath Aerosol Shedding of Highly Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants.Clin Infect Dis2023
37850626SIRT-1 is required for release of enveloped enteroviruses.Elife2023
37581442Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses.mBio2023
36854666Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.Nat Commun2023
34783582An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.Sci Transl Med2022
35618725Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.NPJ Vaccines2022
35962188PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.Commun Biol2022
35130559Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2.Nature2022
34519774Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection.Clin Infect Dis2022
33446655SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.Nat Commun2021
33532768Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.bioRxiv2021
33930332Functional landscape of SARS-CoV-2 cellular restriction.Mol Cell2021
33778258Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms.ACS Omega2021
34548634Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.Nat Microbiol2021
34663813Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.Nat Commun2021
33941899A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics.Nat Biomed Eng2021
34031655Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.bioRxiv2021
34189531Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection.bioRxiv2021
32350036Correction: Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain.Life Sci Alliance2020
33060197Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.Science2020
33184176The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses.Proc Natl Acad Sci U S A2020
33299990Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.bioRxiv2020
32833214Using Yeast to Identify Coronavirus-Host Protein Interactions.Methods Mol Biol2020
32877576Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.N Engl J Med2020
32817221Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.J Virol2020
32188753COVID-19: Knowns, Unknowns, and Questions.mSphere2020
32540901Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.Science2020
30567988Interferon-Induced Transmembrane Protein 1 Restricts Replication of Viruses That Enter Cells via the Plasma Membrane.J Virol2019
31826928Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain.Life Sci Alliance2019
31142674A Yeast Suppressor Screen Used To Identify Mammalian SIRT1 as a Proviral Factor for Middle East Respiratory Syndrome Coronavirus Replication.J Virol2019
27219333Alphavirus Restriction by IFITM Proteins.Traffic2016
24480526IFITM proteins-cellular inhibitors of viral entry.Curr Opin Virol2014
24706778Heat shock protein 90 controls HIV-1 reactivation from latency.Proc Natl Acad Sci U S A2014
25105503A membrane topology model for human interferon inducible transmembrane protein 1.PLoS One2014
  • 1 - 34 of 34

Recommended Authors

Caroline G Williams
College of Medicine, University of Florida
Career Start Year 2018
Number of shared co-authors 8
Andreas S Puschnik
Stanford University School of Medicine
Career Start Year 2013
Number of shared co-authors 19
Chengjin Ye
Texas Biomedical Research Institute
Career Start Year 2013
Number of shared co-authors 21
Hongjie Xia
University of Texas Medical Branch
Career Start Year 2012
Number of shared co-authors 3
Brook E Heaton
Duke University School of Medicine
Career Start Year 2012
Number of shared co-authors 5
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 28
Craig B Wilen
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 7
Kenneth S Plante
University of Texas Medical Branch
Career Start Year 2009
Number of shared co-authors 6
Holly Ramage
Sidney Kimmel Medical College, Thomas Jefferson University
Career Start Year 2009
Number of shared co-authors 8
Carles Mart??nez-Romero
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 12
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 7
Vineet D Menachery
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 7
Mohsan Saeed
Boston University Chobanian and Avedisian School of Medicine
Career Start Year 2007
Number of shared co-authors 2
Colm Atkins
Rutgers University
Career Start Year 2007
Number of shared co-authors 4
Nicholas S Heaton
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 10
Amie J Eisfeld
Influenza Research Institute, University of Wisconsin-Madison
Career Start Year 2006
Number of shared co-authors 3
Sudhakar Agnihothram
National Center for Toxicological Research
Career Start Year 2005
Number of shared co-authors 4
Rachel L Graham
University of North Carolina
Career Start Year 2004
Number of shared co-authors 3
Yaw Shin Ooi
Duke-NUS Medical School
Career Start Year 2003
Number of shared co-authors 6
Alexandra Sch??fer
University of North Carolina at Chapel Hill
Career Start Year 2003
Number of shared co-authors 11
Balaji Manicassamy
University of Iowa
Career Start Year 2002
Number of shared co-authors 15
Shirit Einav
Stanford University School of Medicine
Career Start Year 2002
Number of shared co-authors 3
Priya S Shah
University of California davis
Career Start Year 2002
Number of shared co-authors 11
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 41
Gaya K Amarasinghe
Washington University School of Medicine at St. Louis
Career Start Year 2000
Number of shared co-authors 9
Daisy W Leung
Washington University School of Medicine
Career Start Year 1999
Number of shared co-authors 9
Amy C Sims
The University of North Carolina at Chapel Hill
Career Start Year 1998
Number of shared co-authors 5
Abraham L Brass
University of Massachusetts Medical School
Career Start Year 1995
Number of shared co-authors 9
Lucy Thorne
University College London
Career Start Year 1992
Number of shared co-authors 18
Robert A Davey
Boston University
Career Start Year 1991
Number of shared co-authors 9

Collaborators

Matthew B Frieman
Center for Pathogen Research, University of Maryland School of Medicine
Co-authored papers 27
James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Co-authored papers 15
Holly Hammond
Center for Pathogen Research, University of Maryland School of Medicine
Co-authored papers 9
Adolfo Garc??a-Sastre
Icahn School of Medicine at Mount Sinai
Co-authored papers 3
Michael S Diamond
Washington University School of Medicine
Co-authored papers 2
Rita E Chen
Co-authored papers 2
Pei-Yong Shi
University of Texas Medical Branch
Co-authored papers 2
Ralph S Baric
University of North Carolina
Co-authored papers 2
Romel Rosales
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
James E Crowe
Vanderbilt University Medical Center
Co-authored papers 2
Xuping Xie
University of Texas Medical Branch
Co-authored papers 2
Trey Ideker (CM4AI)
University of California San Diego
Co-authored papers 2
Lisa Miorin
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Pavlo Gilchuk
Vanderbilt University Medical Center
Co-authored papers 2
Boyd L Yount
University of North Carolina at Chapel Hill
Co-authored papers 2
Robert H Carnahan
Vanderbilt University Medical Center
Co-authored papers 2
Kris M White
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Al Ozonoff
Harvard Medical School
Co-authored papers 2
Sirano Dhe-Paganon
Dana-Farber Cancer Institute
Co-authored papers 2
Dan H Barouch
Co-authored papers 2
Sara Cherry
University of Pennsylvania
Co-authored papers 2
Edward C Holmes
Sydney Institute for Infectious Diseases, The University of Sydney
Co-authored papers 2
Hannes Braberg
University of California San Francisco
Co-authored papers 1
Zun Zar Chi Naing
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 1
Jiewei Xu
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 1
Nadia Herrera
University of California san francisco
Co-authored papers 1
Ming Sun
Columbia University
Co-authored papers 1
Loan Doan
University of California san francisco
Co-authored papers 1
Maliheh Safari
University of California san francisco
Co-authored papers 1
Xin Yin
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Release 1.2